Cullinan Associates Inc Vertex Pharmaceuticals Inc Transaction History

Cullinan Associates Inc

$1.81 Billion
Q3 2024

A detailed history of Cullinan Associates Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cullinan Associates Inc holds 54,662 shares of VRTX stock, worth $27.5 Million. This represents 1.41% of its overall portfolio holdings.

Number of Shares

54,662

Previous 55,662 1.8%

Holding current value

$27.5 Million

Previous $26.1 Million 2.56%

% of portfolio

1.41%

Previous 1.49%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	SELL	$460.0 - $505.78 $460,000 - $505,780	-1,000 Reduced 1.8%	54,662 $25.4 Million
Q2 2024 Jul 10, 2024	SELL	$392.81 - $485.53 $241,185 - $298,115	-614 Reduced 1.09%	55,662 $26.1 Million
Q1 2024 Apr 18, 2024	SELL	$407.69 - $446.08 $815,380 - $892,160	-2,000 Reduced 3.43%	56,276 $23.5 Million
Q4 2023 Jan 24, 2024	SELL	$343.0 - $410.68 $960,400 - $1.15 Million	-2,800 Reduced 4.58%	58,276 $23.7 Million
Q3 2023 Oct 11, 2023	SELL	$338.18 - $362.46 $304,362 - $326,214	-900 Reduced 1.45%	61,076 $21.2 Million
Q2 2023 Jul 14, 2023	SELL	$314.42 - $351.91 $817,492 - $914,966	-2,600 Reduced 4.03%	61,976 $21.8 Million
Q1 2023 Apr 05, 2023	SELL	$283.23 - $323.1 $86,385 - $98,545	-305 Reduced 0.47%	64,576 $20.3 Million
Q4 2022 Jan 11, 2023	SELL	$285.76 - $321.48 $5.54 Million - $6.24 Million	-19,400 Reduced 23.02%	64,881 $18.7 Million
Q3 2022 Oct 19, 2022	SELL	$273.83 - $305.53 $1.27 Million - $1.42 Million	-4,650 Reduced 5.23%	84,281 $24.4 Million
Q2 2022 Jul 08, 2022	SELL	$234.96 - $292.55 $2.21 Million - $2.75 Million	-9,385 Reduced 9.55%	88,931 $25.1 Million
Q1 2022 Apr 21, 2022	SELL	$221.42 - $260.97 $131,523 - $155,016	-594 Reduced 0.6%	98,316 $25.7 Million
Q4 2021 Jan 07, 2022	SELL	$177.01 - $223.45 $38,057 - $48,041	-215 Reduced 0.22%	98,910 $21.7 Million
Q3 2021 Oct 08, 2021	SELL	$181.39 - $202.99 $473,427 - $529,803	-2,610 Reduced 2.57%	99,125 $18 Million
Q2 2021 Jul 07, 2021	SELL	$187.49 - $221.1 $506,223 - $596,970	-2,700 Reduced 2.59%	101,735 $20.5 Million
Q1 2021 Apr 20, 2021	BUY	$207.02 - $241.31 $2.24 Million - $2.61 Million	10,800 Added 11.53%	104,435 $22.4 Million
Q4 2020 Jan 14, 2021	BUY	$207.01 - $276.09 $1.02 Million - $1.36 Million	4,925 Added 5.55%	93,635 $22.1 Million
Q3 2020 Oct 09, 2020	SELL	$255.65 - $303.1 $1.45 Million - $1.72 Million	-5,679 Reduced 6.02%	88,710 $24.1 Million
Q2 2020 Jul 07, 2020	BUY	$225.48 - $295.8 $333,033 - $436,896	1,477 Added 1.59%	94,389 $27.4 Million
Q1 2020 Apr 01, 2020	BUY	$199.77 - $247.81 $327,822 - $406,656	1,641 Added 1.8%	92,912 $22.1 Million
Q4 2019 Jan 15, 2020	SELL	$166.71 - $223.91 $1.8 Million - $2.42 Million	-10,824 Reduced 10.6%	91,271 $20 Million
Q2 2019 Jul 16, 2019	SELL	$164.61 - $190.37 $1.38 Million - $1.59 Million	-8,378 Reduced 7.58%	102,095 $18.7 Million
Q1 2019 Apr 30, 2019	SELL	$163.73 - $194.7 $1.11 Million - $1.32 Million	-6,800 Reduced 5.8%	110,473 $20.3 Million
Q4 2018 Jan 11, 2019	BUY	$151.91 - $192.21 $831,251 - $1.05 Million	5,472 Added 4.89%	117,273 $19.4 Million
Q3 2018 Oct 19, 2018	SELL	$167.73 - $192.74 $1.43 Million - $1.65 Million	-8,541 Reduced 7.1%	111,801 $21.5 Million
Q2 2018 Jul 09, 2018	BUY	$145.72 - $169.96 $3.18 Million - $3.7 Million	21,795 Added 22.12%	120,342 $20.5 Million
Q1 2018 Apr 27, 2018	BUY	$151.6 - $177.13 $90,960 - $106,278	600 Added 0.61%	98,547 $16.1 Million
Q4 2017 Jan 17, 2018	BUY	$137.28 - $155.55 $150,047 - $170,016	1,093 Added 1.13%	97,947 $14.7 Million
Q3 2017 Oct 16, 2017	BUY	$148.13 - $162.24 $14.3 Million - $15.7 Million	96,854	96,854 $14.7 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Account

Cullinan Associates Inc Vertex Pharmaceuticals Inc Transaction History